Covid-19: AMU begins Covaxin phase-3 trials, VC registers as 1st volunteer

Principal Investigator Prof Mohammad Shameem said ICMR Covaxin Phase 3 trial is going on after the Phase 1 and Phase 2 trials showed encouraging results

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Press Trust of India Lucknow
2 min read Last Updated : Nov 10 2020 | 10:13 PM IST

As the trial of COVID-19 vaccine enters the third phase, AMU Vice Chancellor Professor Tariq Mansoor on Tuesday got himself registered to be the first volunteer for the Covaxin trials.

The phase 3 trials of Covaxin developed by Bharat Biotech began at JN Medical College and Hospital (JNMCH) of the Aligarh Muslim University (AMU) here.

Prof Tariq Mansoor volunteered himself to motivate and inspire others to come forward, an AMU spokesman said.

Covaxin Phase 3 trial is aimed at evaluating the safety and efficacy of the coronavirus vaccine study led in collaboration with the Indian Council of Medical Research (ICMR) and Bharat Biotech, he said.

Seeking active participation from all age groups and socio-economic background in the clinical trials, the AMU VC said, "By volunteering for a trial or study, one get a chance to participate in ground breaking research and contribute to developing better cure and treatment options."

JNMCH principal Prof Shahid Ali Siddiqui said an ethical committee comprising doctors, social workers and lawyers, has already been constituted to manage the clinical trials. He said the required staff for conducting the vaccine trial has been recruited and the registration of volunteers has also been started from Tuesday.

Principal Investigator Prof Mohammad Shameem said ICMR Covaxin Phase 3 trial is going on after the Phase 1 and Phase 2 trials showed encouraging results.

Volunteers who will undergo the Phase 3 trial will receive travel expenses and other benefits as per ICMR guideline, AMU spokesman said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusAligarh Muslim UniversityCoronavirus Vaccine

First Published: Nov 10 2020 | 10:09 PM IST

Next Story